Compare Indoco Remedies with KOTHARI PROD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs KOTHARI PRODUCTS - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES KOTHARI PRODUCTS INDOCO REMEDIES/
KOTHARI PRODUCTS
 
P/E (TTM) x 127.6 13.4 954.8% View Chart
P/BV x 2.1 0.2 1,228.8% View Chart
Dividend Yield % 0.6 1.5 42.3%  

Financials

 INDOCO REMEDIES   KOTHARI PRODUCTS
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
KOTHARI PRODUCTS
Mar-19
INDOCO REMEDIES/
KOTHARI PRODUCTS
5-Yr Chart
Click to enlarge
High Rs317171 185.7%   
Low Rs17875 237.5%   
Sales per share (Unadj.) Rs113.11,931.9 5.9%  
Earnings per share (Unadj.) Rs4.541.4 10.8%  
Cash flow per share (Unadj.) Rs11.842.5 27.8%  
Dividends per share (Unadj.) Rs1.001.00 100.0%  
Dividend yield (eoy) %0.40.8 49.6%  
Book value per share (Unadj.) Rs73.2378.7 19.3%  
Shares outstanding (eoy) m92.1529.84 308.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.20.1 3,442.9%   
Avg P/E ratio x55.53.0 1,868.2%  
P/CF ratio (eoy) x21.02.9 724.5%  
Price / Book Value ratio x3.40.3 1,041.9%  
Dividend payout %22.42.4 927.1%   
Avg Mkt Cap Rs m22,8303,669 622.3%   
No. of employees `0005.50.1 8,798.4%   
Total wages/salary Rs m2,20968 3,263.1%   
Avg. sales/employee Rs Th1,910.1929,817.7 0.2%   
Avg. wages/employee Rs Th405.01,091.9 37.1%   
Avg. net profit/employee Rs Th75.519,930.6 0.4%   
INCOME DATA
Net Sales Rs m10,41957,649 18.1%  
Other income Rs m47334 14.0%   
Total revenues Rs m10,46657,983 18.1%   
Gross profit Rs m1,3491,889 71.4%  
Depreciation Rs m67732 2,129.2%   
Interest Rs m235588 40.0%   
Profit before tax Rs m4841,603 30.2%   
Minority Interest Rs m022 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m72389 18.6%   
Profit after tax Rs m4121,236 33.3%  
Gross profit margin %12.93.3 395.2%  
Effective tax rate %15.024.3 61.7%   
Net profit margin %4.02.1 184.3%  
BALANCE SHEET DATA
Current assets Rs m5,37329,472 18.2%   
Current liabilities Rs m4,15716,677 24.9%   
Net working cap to sales %11.722.2 52.6%  
Current ratio x1.31.8 73.1%  
Inventory Days Days6810 674.9%  
Debtors Days Days73148 49.0%  
Net fixed assets Rs m6,2441,676 372.6%   
Share capital Rs m184298 61.8%   
"Free" reserves Rs m6,56611,003 59.7%   
Net worth Rs m6,75011,301 59.7%   
Long term debt Rs m1,2334,845 25.4%   
Total assets Rs m12,36332,853 37.6%  
Interest coverage x3.13.7 82.1%   
Debt to equity ratio x0.20.4 42.6%  
Sales to assets ratio x0.81.8 48.0%   
Return on assets %5.25.6 94.2%  
Return on equity %6.110.9 55.8%  
Return on capital %9.013.7 65.7%  
Exports to sales %048.5 0.0%   
Imports to sales %055.0 0.0%   
Exports (fob) Rs mNA27,970 0.0%   
Imports (cif) Rs mNA31,732 0.0%   
Fx inflow Rs m3,76227,970 13.5%   
Fx outflow Rs m1,14331,733 3.6%   
Net fx Rs m2,619-3,763 -69.6%   
CASH FLOW
From Operations Rs m1,227-12,718 -9.6%  
From Investments Rs m-1,3608,140 -16.7%  
From Financial Activity Rs m-3885,482 -7.1%  
Net Cashflow Rs m-521905 -57.6%  

Share Holding

Indian Promoters % 59.2 75.0 78.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 12.5 0.0 -  
FIIs % 6.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 25.0 89.6%  
Shareholders   12,805 7,011 182.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   STC INDIA  TVS SRICHAKRA  EDELWEISS FINANCIAL  NALWA SONS INV  CHOLAMANDALAM INVEST.  



Today's Market

Sensex Slumps 470 Points; Energy and Banking Stocks Witness Selling(Closing)

Indian share markets witnessed negative trading activity throughout the day and ended deep in the red. The BSE Sensex fell over 550 points intraday and breached the 36,000 mark.

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

KOTHARI PRODUCTS Announces Quarterly Results (3QFY19); Net Profit Down 120.7% (Quarterly Result Update)

Feb 15, 2019 | Updated on Feb 15, 2019

For the quarter ended December 2018, KOTHARI PRODUCTS has posted a net profit of Rs 32 m (down 120.7% YoY). Sales on the other hand came in at Rs 8 bn (down 27.2% YoY). Read on for a complete analysis of KOTHARI PRODUCTS's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (3QFY19); Net Profit Down 76.4% (Quarterly Result Update)

Jan 24, 2019 | Updated on Jan 24, 2019

For the quarter ended December 2018, INDOCO REMEDIES has posted a net profit of Rs 53 m (down 76.4% YoY). Sales on the other hand came in at Rs 3 bn (down 5.6% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Sep 19, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS